Recent

% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

dave59isok 1 post  |  Last Activity: Jan 30, 2015 11:59 AM Member since: Oct 18, 2008
  • Done
    PARIS--(BUSINESS WIRE)--
    Regulatory News:
    Cellectis SA (ALCLS.PA) (Alternext:ALCLS.PA) announces that it has entered into an exclusive license agreement with The Ohio State University, through the Ohio State Innovation Foundation, to develop and commercialize chimeric antigen receptor (CAR) technology targeting multiple myeloma cells.
    The CAR technology licensed to Cellectis is related to CS1, an antigen that is over-expressed in multiple myeloma cells. Cellectis intends to pursue the development of a CS1 CAR T-cell program for this targeted indication.

    Sentiment: Buy

VRTX
125.07-3.87(-3.00%)Apr 17 4:00 PMEDT